{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=13&state=Texas",
    "query": {
      "state": "Texas",
      "city": "Houston",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 22473,
    "total_pages": 2248,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=14&state=Texas&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=12&state=Texas&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T12:28:57.763Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00617552",
      "title": "Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postoperative Ileus"
      ],
      "interventions": [
        {
          "name": "5% dextrose in water",
          "type": "DRUG"
        },
        {
          "name": "TZP-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tranzyme, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 267,
      "start_date": "2007-07",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2012-12-07",
      "last_synced_at": "2026-11-02T12:28:57.763Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Miami, Florida • Ocala, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00617552"
    },
    {
      "nct_id": "NCT02096055",
      "title": "Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "70 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2014-04-04",
      "completion_date": "2020-11-24",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-11-02T12:28:57.763Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096055"
    },
    {
      "nct_id": "NCT02734615",
      "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic ER+ Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LSZ102",
          "type": "DRUG"
        },
        {
          "name": "LEE011",
          "type": "DRUG"
        },
        {
          "name": "BYL719",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 199,
      "start_date": "2016-06-14",
      "completion_date": "2021-09-13",
      "has_results": false,
      "last_update_posted_date": "2022-08-01",
      "last_synced_at": "2026-11-02T12:28:57.763Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02734615"
    },
    {
      "nct_id": "NCT02548117",
      "title": "H-36731: Finasteride in Management of Elevated Red Blood Cells",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ERYTHROCYTOSIS"
      ],
      "interventions": [
        {
          "name": "Finasteride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2016-02",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-11-02T12:28:57.763Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02548117"
    },
    {
      "nct_id": "NCT00023374",
      "title": "TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "Ethambutol",
          "type": "DRUG"
        },
        {
          "name": "REZ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2000-08",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2011-08-03",
      "last_synced_at": "2026-11-02T12:28:57.763Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00023374"
    },
    {
      "nct_id": "NCT00086190",
      "title": "Study of Antidepressants in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease",
        "Depression"
      ],
      "interventions": [
        {
          "name": "paroxetine",
          "type": "DRUG"
        },
        {
          "name": "venlafaxine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2005-06",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2013-01-04",
      "last_synced_at": "2026-11-02T12:28:57.763Z",
      "location_count": 15,
      "location_summary": "San Francisco, California • Gainesville, Florida • Miami, Florida + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00086190"
    },
    {
      "nct_id": "NCT01623349",
      "title": "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BKM120 and Olaparib",
          "type": "DRUG"
        },
        {
          "name": "BYL719 and Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2012-09",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2021-02-10",
      "last_synced_at": "2026-11-02T12:28:57.763Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01623349"
    },
    {
      "nct_id": "NCT05084638",
      "title": "Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapse Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 180,
      "start_date": "2022-01-25",
      "completion_date": "2026-02-11",
      "has_results": true,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-11-02T12:28:57.763Z",
      "location_count": 35,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05084638"
    },
    {
      "nct_id": "NCT00483548",
      "title": "Adjunctive Ziprasidone in the Treatment of Bipolar I Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Depression, Bipolar"
      ],
      "interventions": [
        {
          "name": "Ziprasidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2007-10",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2021-03-10",
      "last_synced_at": "2026-11-02T12:28:57.763Z",
      "location_count": 60,
      "location_summary": "Chandler, Arizona • Litchfield Park, Arizona • Little Rock, Arkansas + 50 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00483548"
    },
    {
      "nct_id": "NCT01400425",
      "title": "Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Progressive Cognitive Decline"
      ],
      "interventions": [
        {
          "name": "florbetapir F 18",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avid Radiopharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 239,
      "start_date": "2011-07",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2013-03-29",
      "last_synced_at": "2026-11-02T12:28:57.763Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01400425"
    }
  ]
}